FDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioid

FDA will review BPC-157, TB-500, Semax, and other peptides in July as it considers additions to the 503A Bulks List.

martedì 7 luglio 2026 New tab

424 words~2 min read

The U.S. Food and Drug Administration (FDA) will hold a two-day advisory committee meeting on July 23 and 24 to evaluate several peptide-related bulk drug substances for possible inclusion on the 503A Bulks List, a key list that determines which bulk ingredients may be used in certain compounded medications.

The discussions will cover substances nominated for a range of conditions, from ulcerative colitis and wound healing to obesity, insomnia and opioid withdrawal.

On July 23, the committee will review BPC-157-related substances, including the free base and acetate forms, for use in ulcerative colitis.

FDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioid

FDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioid

Other newsrooms on this story

Related reading

FDA reviewers oppose allowing seven peptides for compounding

Peptide exceptionalism is a dangerous FDA loophole

Compounder Olympia Pharmaceuticals eyes peptide opportunity

FDA advisory committee for peptides stocked with conflicts of interest

FDA Staffers Oppose Proposed Clearance Of Peptides

FDA panel on peptides will include experts who promote the unproven chemicals…

Other newsrooms on this story

Related reading

FDA reviewers oppose allowing seven peptides for compounding

Peptide exceptionalism is a dangerous FDA loophole

Compounder Olympia Pharmaceuticals eyes peptide opportunity

FDA advisory committee for peptides stocked with conflicts of interest

FDA Staffers Oppose Proposed Clearance Of Peptides

FDA panel on peptides will include experts who promote the unproven chemicals…